Zug, Zug, Switzerland HBM Partners is the famous VC, which was founded in 2001. The venture was found in North America in Cayman Islands. The main department of described VC is located in the Grand Cayman.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the HBM Partners, startups are often financed by InterWest Partners, HBM Healthcare Investments AG, Correlation Ventures. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Correlation Ventures, Advanced Technology Ventures. In the next rounds fund is usually obtained by Correlation Ventures, KfW, InterWest Partners.
We also calculated 4 valuable employees in our database.
We can highlight the next thriving fund investment areas, such as Health Diagnostics, Medical. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline ITeos Therapeutics, Iconic Therapeutics, Newron Pharmaceuticals The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
The fund is constantly included in less than 2 deals per year. This HBM Partners works on 13 percentage points more the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2004. Considering the real fund results, this VC is 3 percentage points less often commits exit comparing to other organizations.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Alpha Edison | California, Los Angeles, United States |
| Andover Ventures | - |
| Beijing Qianxiang Yixin Technology Development | Beijing, Beijing, China |
| Canadian Pacific | Alberta, Calgary, Canada |
| Fast Forward | California, San Francisco, United States |
| FNQ Angels | Australia, Cairns, Queensland |
| Fuyang Zhengqi | - |
| Government of Slovak Republic | District of Zvolen, Region of Banská Bystrica, Slovakia |
| Jingui Yinye | Chenzhou, China, Hunan |
| Mannheim Holdings | - |
| Mitsui Mining & Smelting | Japan, Tokyo |
| Morgan Stanley Investment Management | New York, New York, United States |
| MSP Bank | - |
| Nantahala Capital Management | Connecticut, New York, United States |
| Plug N Play | New York, United States, Valley Cottage |
| Rebright Partners | Chiyoda, Japan |
| Ruikangsheng Touzi | China, Hubei, Wuhan |
| SV Investment Partners | Connecticut, Greenwich, United States |
| Westport Capital Partners | Connecticut, United States, Wilton |
| YIMI | China, Guangdong, Guangzhou |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
1000Farmacie | $10M | 02 Jun 2023 | Milan, Lombardy, Italy | ||
Sphingotec GmbH | $1M | 14 Mar 2023 | Hohen Neuendorf, Brandenburg, Germany | ||
Genalyte | $1M | 07 Mar 2023 | San Diego, California, United States | ||
Upstream Bio | $8M | 10 Feb 2023 | Waltham, Massachusetts, United States | ||
Ignis Therapeutics | $2M | 20 Jan 2023 | Shanghai, Shanghai, China | ||
Farmalisto | 25 Apr 2022 | Buenaventura, Valle del Cauca, Colombia | |||
Neuron23 | $100M | 30 Mar 2022 | San Francisco, California, United States | ||
Numab | $109M | 19 May 2021 | Zurich, Switzerland | ||
| $80M | 16 Dec 2020 | San Francisco, California, United States |
– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
1000Farmacie | $10M | 02 Jun 2023 | Milan, Lombardy, Italy | ||
Sphingotec GmbH | $1M | 14 Mar 2023 | Hohen Neuendorf, Brandenburg, Germany | ||
Genalyte | $1M | 07 Mar 2023 | San Diego, California, United States | ||
Upstream Bio | $8M | 10 Feb 2023 | Waltham, Massachusetts, United States | ||
Ignis Therapeutics | $2M | 20 Jan 2023 | Shanghai, Shanghai, China | ||
Farmalisto | 25 Apr 2022 | Buenaventura, Valle del Cauca, Colombia | |||
Neuron23 | $100M | 30 Mar 2022 | San Francisco, California, United States | ||
Numab | $109M | 19 May 2021 | Zurich, Switzerland | ||
| $80M | 16 Dec 2020 | San Francisco, California, United States |
